CDH10

Summary

CDH10 (cadherin 10, HGNC:1749) is a protein-coding gene on chromosome 5p14.2-p14.1, encoding Cadherin-10 (Q9Y6N8). Cadherins are calcium-dependent cell adhesion proteins.

This gene encodes a type II classical cadherin of the cadherin superfamily. Alternative splicing of this gene results in multiple transcript variants. At least one of these variants encodes a preproprotein that is proteolytically processed to generate the mature cadherin protein. These integral membrane proteins mediate calcium-dependent cell-cell adhesion and are composed of a large N-terminal extracellular domain, a single membrane-spanning domain, and a small, highly conserved C-terminal cytoplasmic domain. The extracellular domain consists of 5 subdomains, each containing a cadherin motif, and appears to determine the specificity of the protein’s homophilic cell adhesion activity. Type II (atypical) cadherins are defined based on their lack of a histidine-alanine-valine (HAV) cell adhesion recognition sequence specific to type I cadherins. This particular cadherin is predominantly expressed in brain and is putatively involved in synaptic adhesions, axon outgrowth and guidance. Mutations in this gene may be associated with lung squamous cell carcinoma and colorectal cancer in human patients.

Source: NCBI Gene 1008 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 100 total — 1 pathogenic
• Phenotypes (HPO): 1
• Cancer driver (intOGen): activating (oncogene-like) across 4 cancer types
• MANE Select transcript: NM_006727

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1749
Approved symbol	CDH10
Name	cadherin 10
Location	5p14.2-p14.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000040731
Ensembl biotype	protein_coding
OMIM	604555
Entrez	1008

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 2 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron, 1 nonsense_mediated_decay

ENST00000264463, ENST00000502921, ENST00000503958, ENST00000510477, ENST00000965911

RefSeq mRNA: 4 — MANE Select: NM_006727 NM_001317222, NM_001317224, NM_001362460, NM_006727

CCDS: CCDS3892

Canonical transcript exons

ENST00000264463 — 12 exons

Exon	Start	End
ENSE00000970943	24537380	24537674
ENSE00000970946	24511327	24511514
ENSE00000970947	24509566	24509819
ENSE00000970948	24505112	24505248
ENSE00001156334	24593260	24593613
ENSE00001361706	24644594	24644978
ENSE00001387472	24487100	24488153
ENSE00001629749	24535112	24535279
ENSE00001725744	24535703	24535822
ENSE00003509431	24491576	24491827
ENSE00003537047	24498398	24498519
ENSE00003556727	24492817	24492925

Expression profiles

Bgee: expression breadth ubiquitous, 172 present calls, max score 95.85.

FANTOM5 (CAGE): breadth broad, TPM avg 5.5218 / max 502.3765, expressed in 525 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
61121	2.9331	442
61122	0.9020	276
61117	0.5452	113
61120	0.4813	187
61119	0.3580	122
61118	0.1486	58
203506	0.0979	54
203505	0.0556	26

Top tissues by expression

270 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	95.85	gold quality
middle temporal gyrus	UBERON:0002771	95.55	gold quality
Brodmann (1909) area 46	UBERON:0006483	93.51	gold quality
orbitofrontal cortex	UBERON:0004167	92.93	gold quality
superior frontal gyrus	UBERON:0002661	92.40	gold quality
cerebellar hemisphere	UBERON:0002245	91.51	gold quality
cerebellar cortex	UBERON:0002129	91.48	gold quality
entorhinal cortex	UBERON:0002728	91.32	gold quality
cerebellum	UBERON:0002037	91.10	gold quality
right hemisphere of cerebellum	UBERON:0014890	91.07	gold quality
prefrontal cortex	UBERON:0000451	90.12	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.08	gold quality
Brodmann (1909) area 9	UBERON:0013540	90.01	gold quality
frontal cortex	UBERON:0001870	89.59	gold quality
primary visual cortex	UBERON:0002436	89.56	gold quality
postcentral gyrus	UBERON:0002581	89.41	gold quality
neocortex	UBERON:0001950	88.95	gold quality
endothelial cell	CL:0000115	88.44	gold quality
parietal lobe	UBERON:0001872	88.18	gold quality
cerebral cortex	UBERON:0000956	88.14	gold quality
cerebellar vermis	UBERON:0004720	88.01	gold quality
anterior cingulate cortex	UBERON:0009835	87.68	gold quality
cingulate cortex	UBERON:0003027	87.62	gold quality
right frontal lobe	UBERON:0002810	87.19	gold quality
temporal lobe	UBERON:0001871	87.01	gold quality
CA1 field of hippocampus	UBERON:0003881	86.71	gold quality
occipital lobe	UBERON:0002021	86.26	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	84.82	gold quality
amygdala	UBERON:0001876	84.64	gold quality
telencephalon	UBERON:0001893	84.63	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	62.68
E-ANND-3	no	5.22
E-MTAB-6058	no	2.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

56 targeting CDH10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-8062	99.88	68.43	995
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-MIR-579-3P	99.86	71.66	3628
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-6086	99.70	65.38	699
HSA-MIR-377-5P	99.70	65.28	712
HSA-MIR-587	99.64	70.86	2611

Literature-anchored findings (GeneRIF, showing 4)

• The CC genotype of rs4307059 located in the region between CDH9 and CDH10 is associated with completed suicide in a Polish cohort (PMID:22846907)
• Unconventional CDH10, CDH24 and DCHS2 genes harbored frameshift mutations. (PMID:24898286)
• Loss of CDH10 gene is associated with pancreatic ductal adenocarcinomas. (PMID:28124395)
• G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome. (PMID:32292512)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdh10a	ENSDARG00000055843
danio_rerio		ENSDARG00000103903
mus_musculus	Cdh10	ENSMUSG00000022321
rattus_norvegicus	Cdh10	ENSRNOG00000009771

Paralogs (33): CDH1 (ENSG00000039068), CDH3 (ENSG00000062038), CDH19 (ENSG00000071991), CDHR2 (ENSG00000074276), CDH17 (ENSG00000079112), CDH7 (ENSG00000081138), PCDH11Y (ENSG00000099715), CDHR5 (ENSG00000099834), CDH20 (ENSG00000101542), PCDH11X (ENSG00000102290), CDH23 (ENSG00000107736), CDH9 (ENSG00000113100), CDH6 (ENSG00000113361), CDH26 (ENSG00000124215), CDHR3 (ENSG00000128536), CDH15 (ENSG00000129910), CDH24 (ENSG00000139880), CDH11 (ENSG00000140937), CDH13 (ENSG00000140945), CDH18 (ENSG00000145526), CDHR1 (ENSG00000148600), CDH22 (ENSG00000149654), CDH8 (ENSG00000150394), CDH12 (ENSG00000154162), PCDH1 (ENSG00000156453), DCHS1 (ENSG00000166341), PCDH7 (ENSG00000169851), CDH2 (ENSG00000170558), CDH4 (ENSG00000179242), CDH5 (ENSG00000179776), PCDH9 (ENSG00000184226), DCHS2 (ENSG00000197410), PCDH20 (ENSG00000280165)

Protein

Protein identifiers

Cadherin-10 — Q9Y6N8 (reviewed: Q9Y6N8)

Alternative names: T2-cadherin

All UniProt accessions (4): D6RJG0, Q9Y6N8, X5D8X5, X5DNG6

UniProt curated annotations — full annotation on UniProt →

Function. Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.

Subcellular location. Cell membrane.

Tissue specificity. Predominantly expressed in brain. Also found in adult and fetal kidney. Very low levels detected in prostate and fetal lung.

Domain organisation. Three calcium ions are usually bound at the interface of each cadherin domain and rigidify the connections, imparting a strong curvature to the full-length ectodomain.

RefSeq proteins (4): NP_001304151, NP_001304153, NP_001349389, NP_006718* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000233	Cadherin_Y-type_LIR	Domain
IPR002126	Cadherin-like_dom	Domain
IPR015919	Cadherin-like_sf	Homologous_superfamily
IPR020894	Cadherin_CS	Conserved_site
IPR027397	Catenin-bd_sf	Homologous_superfamily
IPR039808	Cadherin	Family

Pfam: PF00028, PF01049

UniProt features (21 total): domain 5, glycosylation site 4, modified residue 2, sequence variant 2, sequence conflict 2, topological domain 2, signal peptide 1, propeptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y6N8-F1	78.29	0.49

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 784, 788

Glycosylation sites (4): 256, 438, 456, 534

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-418990	Adherens junctions interactions
R-HSA-1500931	Cell-Cell communication
R-HSA-421270	Cell-cell junction organization
R-HSA-446728	Cell junction organization

MSigDB gene sets: 165 (showing top): FISCHER_G1_S_CELL_CYCLE, GCANCTGNY_MYOD_Q6, XU_HGF_TARGETS_REPRESSED_BY_AKT1_DN, CHANDRAN_METASTASIS_DN, GOBP_CALCIUM_DEPENDENT_CELL_CELL_ADHESION, NKX61_01, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, GOBP_CELL_CELL_ADHESION, GOBP_CELL_JUNCTION_ORGANIZATION, CATTTCA_MIR203, NF1_Q6_01, TGCTGAY_UNKNOWN, TGIF_01, FOXJ2_01, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN

GO Biological Process (10): cell morphogenesis (GO:0000902), cell-cell junction assembly (GO:0007043), homophilic cell-cell adhesion (GO:0007156), calcium-dependent cell-cell adhesion (GO:0016339), cell migration (GO:0016477), adherens junction organization (GO:0034332), cell-cell adhesion mediated by cadherin (GO:0044331), cell-cell adhesion (GO:0098609), synaptic membrane adhesion (GO:0099560), cell adhesion (GO:0007155)

GO Molecular Function (4): calcium ion binding (GO:0005509), beta-catenin binding (GO:0008013), cadherin binding (GO:0045296), metal ion binding (GO:0046872)

GO Cellular Component (9): plasma membrane (GO:0005886), adherens junction (GO:0005912), catenin complex (GO:0016342), presynaptic active zone membrane (GO:0048787), glutamatergic synapse (GO:0098978), GABA-ergic synapse (GO:0098982), postsynaptic specialization membrane (GO:0099634), membrane (GO:0016020), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Cell-cell junction organization	1
Cell junction organization	1
Cell-Cell communication	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	4
cell-cell junction organization	2
synaptic membrane	2
synapse	2
anatomical structure morphogenesis	1
cell junction assembly	1
cell motility	1
cell adhesion	1
synapse organization	1
cellular process	1
metal ion binding	1
protein binding	1
cell adhesion molecule binding	1
cation binding	1
membrane	1
cell periphery	1
cell-cell junction	1
extrinsic component of plasma membrane	1
plasma membrane protein complex	1
presynaptic membrane	1
presynaptic active zone	1
postsynaptic membrane	1
postsynaptic specialization	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

1304 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDH10	TAS2R1	Q9NYW7	788
CDH10	SEMA5A	Q13591	741
CDH10	NLGN4X	Q8N0W4	739
CDH10	NLGN3	Q9NZ94	711
CDH10	CNTN4	Q8IWV2	707
CDH10	NLGN1	Q8N2Q7	668
CDH10	ASTN2	O75129	661
CDH10	CDH15	P55291	656
CDH10	NRXN1	Q9ULB1	641
CDH10	CDH2	P19022	635
CDH10	CDH19	Q9H159	632
CDH10	FBXO40	Q9UH90	631
CDH10	CDH20	Q9HBT6	626
CDH10	CDH7	Q9ULB5	626
CDH10	COP1	Q8NHY2	596

IntAct

7 interactions, top by confidence:

A	B	Type	Score
CTNNB1	JUP	psi-mi:“MI:0914”(association)	0.610
Cdh1	ARVCF	psi-mi:“MI:0914”(association)	0.350
CTNNA3	ARVCF	psi-mi:“MI:0914”(association)	0.350
CTNNB1	IGLL5	psi-mi:“MI:0914”(association)	0.350
CDH10	COPS6	psi-mi:“MI:0915”(physical association)	0.000
CDH10	PTN	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (11): CDH10 (Affinity Capture-MS), CDH10 (Affinity Capture-MS), CDH10 (Affinity Capture-MS), COPS6 (Two-hybrid), PTN (Two-hybrid), CDH10 (Affinity Capture-Western), CDH10 (Affinity Capture-MS), CDH10 (Affinity Capture-MS), CDH10 (Affinity Capture-MS), CDH10 (Protein-peptide), JUP (Two-hybrid)

ESM2 similar proteins: A0A8M2BIB6, F1QSQ0, F8W3X3, H2EQR6, O35902, O54800, O55111, O93319, P32926, P33545, P55280, P55285, P55286, P55287, P55288, P55289, P55292, P55849, P55850, P70407, P70408, P79995, P97291, P97326, Q01107, Q02413, Q02487, Q08554, Q08DJ5, Q13634, Q14126, Q14574, Q28060, Q3SWX5, Q5DWV1, Q5RJH3, Q61495, Q68SP4, Q6W3B0, Q7TMD7

Diamond homologs: A0A8M2BIB6, B0KW95, B2KI42, B4USZ0, F1PAA9, F1QSQ0, O02840, O35902, O54800, O55075, O55111, O93319, P08641, P09803, P10287, P10288, P12830, P15116, P19022, P19534, P19535, P20310, P22223, P24503, P30944, P32926, P33145, P33146, P33147, P33148, P33150, P33151, P33152, P33545, P39038, P55280, P55283, P55284, P55285, P55286

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
calcium(2+)	“up-regulates activity”	CDH10	“chemical activation”
CDH10	“up-regulates activity”	CTNNB1	binding

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 4 cancer types — LUAD, LUSC, PAAD, UCEC.

Clinical variants and AI predictions

ClinVar

100 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	79
Likely benign	4
Benign	4

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
59605	GRCh38/hg38 5p14.3-14.1(chr5:23279693-26849830)x1	Pathogenic

SpliceAI

2711 predictions. Top by Δscore:

Variant	Effect	Δscore
5:24488149:TATAA:T	acceptor_gain	1.0000
5:24488150:ATAA:A	acceptor_gain	1.0000
5:24488151:TAA:T	acceptor_gain	1.0000
5:24488152:AA:A	acceptor_gain	1.0000
5:24488154:C:CC	acceptor_gain	1.0000
5:24488155:T:C	acceptor_gain	1.0000
5:24488155:T:G	acceptor_loss	1.0000
5:24488155:T:TC	acceptor_gain	1.0000
5:24491574:AC:A	donor_gain	1.0000
5:24491575:CC:C	donor_gain	1.0000
5:24498391:GGCTT:G	donor_loss	1.0000
5:24498392:GCTTA:G	donor_loss	1.0000
5:24498393:CTTA:C	donor_loss	1.0000
5:24498394:TTA:T	donor_loss	1.0000
5:24498395:T:TG	donor_loss	1.0000
5:24498396:AC:A	donor_loss	1.0000
5:24498516:TTGT:T	acceptor_gain	1.0000
5:24498517:TGT:T	acceptor_gain	1.0000
5:24498520:C:CC	acceptor_gain	1.0000
5:24505110:A:AC	donor_gain	1.0000
5:24505111:C:CC	donor_gain	1.0000
5:24509816:GTGG:G	acceptor_gain	1.0000
5:24509817:TGG:T	acceptor_gain	1.0000
5:24509817:TGGCT:T	acceptor_loss	1.0000
5:24509818:GG:G	acceptor_gain	1.0000
5:24509818:GGCTG:G	acceptor_loss	1.0000
5:24509819:GC:G	acceptor_loss	1.0000
5:24509820:C:CC	acceptor_gain	1.0000
5:24509820:CT:C	acceptor_loss	1.0000
5:24509822:G:C	acceptor_gain	1.0000

AlphaMissense

5198 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:24535204:T:G	D241A	1.000
5:24535205:C:G	D241H	1.000
5:24535210:G:T	A239D	1.000
5:24535211:C:G	A239P	1.000
5:24535216:A:T	I237N	1.000
5:24535273:A:T	I218N	1.000
5:24535723:A:G	F209S	1.000
5:24535751:A:C	Y200D	1.000
5:24537433:G:T	P158Q	1.000
5:24537442:T:A	D155V	1.000
5:24537442:T:C	D155G	1.000
5:24537442:T:G	D155A	1.000
5:24537443:C:G	D155H	1.000
5:24537444:A:C	N154K	1.000
5:24537444:A:T	N154K	1.000
5:24537450:A:C	D152E	1.000
5:24537450:A:T	D152E	1.000
5:24537451:T:A	D152V	1.000
5:24537451:T:G	D152A	1.000
5:24537452:C:G	D152H	1.000
5:24537463:A:T	I148N	1.000
5:24537468:A:C	F146L	1.000
5:24537468:A:T	F146L	1.000
5:24537469:A:G	F146S	1.000
5:24537470:A:G	F146L	1.000
5:24537526:A:G	L127P	1.000
5:24537547:T:A	E120V	1.000
5:24537550:C:A	R119M	1.000
5:24537550:C:G	R119T	1.000
5:24537574:A:C	I111S	1.000

dbSNP variants (sampled 300 via entrez): RS1000001711 (5:24564180 C>A), RS1000039864 (5:24604015 T>C), RS1000055521 (5:24633745 T>C,G), RS1000081298 (5:24531300 C>T), RS1000087877 (5:24552248 T>A,C), RS1000088976 (5:24616547 T>C,G), RS1000129782 (5:24637231 A>G), RS1000137333 (5:24546264 C>T), RS1000156677 (5:24506582 A>G), RS1000160486 (5:24492527 G>A), RS1000172009 (5:24529867 A>G), RS1000174471 (5:24490965 T>C), RS1000230621 (5:24570664 G>GTA), RS1000241390 (5:24610311 G>A,T), RS1000248041 (5:24609182 T>C)

Disease associations

OMIM: gene MIM:604555 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): hyperopia (MONDO:0004891), obesity disorder (MONDO:0011122)

Orphanet (2): Obesity due to melanocortin 4 receptor deficiency (Orphanet:71529), NON RARE IN EUROPE: Non rare obesity (Orphanet:521399)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001513	Obesity

GWAS associations

11 associations (top):

Study	Trait	p-value
GCST000382_1	Autism	2.000000e-10
GCST001800_8	β2-Glycoprotein I (β2-GPI) plasma levels	2.000000e-06
GCST002451_2	Obsessive-compulsive disorder	2.000000e-06
GCST003944_28	Hepcidin/ferritin ratio	6.000000e-06
GCST005588_26	Idiopathic dilated cardiomyopathy	3.000000e-06
GCST005956_56	Waist-to-hip ratio adjusted for BMI	2.000000e-06
GCST005959_31	Waist-to-hip ratio adjusted for BMI x sex interaction	4.000000e-06
GCST007325_71	General risk tolerance (MTAG)	5.000000e-10
GCST008465_7	Anorexia nervosa	3.000000e-08
GCST010570_4	Polycystic ovary syndrome (reproductive subtype)	1.000000e-08
GCST011743_73	HDL cholesterol levels in HIV infection	4.000000e-06

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0004555	glycoprotein measurement
EFO:0007901	hepcidin:ferritin ratio
EFO:0009094	idiopathic dilated cardiomyopathy
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008343	sex interaction measurement
EFO:0008579	risk-taking behaviour
EFO:0004612	high density lipoprotein cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006956	Hyperopia	C11.744.479

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, decreases methylation, affects cotreatment, increases expression	8
Benzo(a)pyrene	increases expression	3
mercuric bromide	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Rotenone	decreases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
methylmercuric chloride	decreases expression	1
ascorbate-2-phosphate	affects binding, affects cotreatment, increases expression	1
trichostatin A	increases expression	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
potassium chromate(VI)	increases expression	1
4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid	affects cotreatment, increases expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	decreases expression	1
2-palmitoylglycerol	increases expression	1
fenpyroximate	decreases expression	1
4-chloro-N-((4-(1,1-dimethylethyl)phenyl)methyl)-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide	decreases expression	1
Chir 99021	increases expression, affects binding, affects cotreatment	1
pyrimidifen	decreases expression	1
thifluzamide	decreases expression	1
pyrachlostrobin	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
XAV939	affects binding, affects cotreatment, increases expression	1
LDN 193189	affects cotreatment, increases expression	1
picoxystrobin	decreases expression	1
3-(4-pyridyl)-1H-indole	affects cotreatment, increases expression	1
Temozolomide	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00347204	PHASE4	COMPLETED	Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
NCT00455455	PHASE4	COMPLETED	Corneal and Conjunctival Sensitivity and Staining Study
NCT00937105	PHASE4	COMPLETED	Daily Wear Corneal Infiltrative Event Study
NCT01387360	PHASE4	COMPLETED	Presbyopic Supracor Treatment for Near Myopic/Hyperopic Pseudophakic Eyes
NCT01977807	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK
NCT02071576	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK
NCT02112968	PHASE4	UNKNOWN	A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia
NCT03881670	PHASE4	COMPLETED	On-Eye Optical Quality of Lotrafilcon B Lenses Over 12 Hours
NCT04208750	PHASE4	COMPLETED	Clinical Investigation of the Vision-R800 Device.
NCT04283331	PHASE4	UNKNOWN	Anesthetic Impregnated Bandage Soft Contact Lens (BSCL) in Pain Management After Photorefractive Keratectomy (PRK)
NCT00076362	PHASE4	COMPLETED	Pediatric Hypothalamic Obesity
NCT00079547	PHASE4	COMPLETED	The Safety and Effectiveness of Low and High Carbohydrate Diets
NCT00115063	PHASE4	TERMINATED	LOSS- Louisiana Obese Subjects Study
NCT00134303	PHASE4	COMPLETED	Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
NCT00143936	PHASE4	COMPLETED	The Safety and Efficacy of Low and High Carbohydrate Diets
NCT00143962	PHASE4	COMPLETED	Comparison of Two Approaches to Weight Loss Follow-Up Study
NCT00152360	PHASE4	COMPLETED	The Effect of Xenical on Weight and Risk Factors
NCT00176306	PHASE4	COMPLETED	Levofloxacin Pharmacokinetics (PK) in the Severely Obese
NCT00203450	PHASE4	COMPLETED	Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
NCT00205504	PHASE4	COMPLETED	Oral Contraceptives in the Metabolic Syndrome
NCT00229229	PHASE4	TERMINATED	Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease
NCT00234988	PHASE4	COMPLETED	A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
NCT00264589	PHASE4	COMPLETED	Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes
NCT00288873	PHASE4	COMPLETED	Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
NCT00298857	PHASE4	TERMINATED	A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights
NCT00315146	PHASE4	COMPLETED	Optimizing Body Composition for Function in Older Adults
NCT00319202	PHASE4	TERMINATED	Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects
NCT00327912	PHASE4	UNKNOWN	Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity
NCT00352287	PHASE4	COMPLETED	Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
NCT00353054	PHASE4	COMPLETED	Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
NCT00390637	PHASE4	COMPLETED	Diet, Obesity and Genes (DiOGenes)
NCT00415688	PHASE4	COMPLETED	Lifestyle Modification for Obesity-Related Type 2 Diabetes
NCT00433641	PHASE4	COMPLETED	Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
NCT00440375	PHASE4	COMPLETED	Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
NCT00453557	PHASE4	COMPLETED	Mechanism of Growth Hormone Effects on Adipose Tissue
NCT00456885	PHASE4	COMPLETED	The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
NCT00463112	PHASE4	COMPLETED	Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS
NCT00512187	PHASE4	COMPLETED	Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
NCT00516919	PHASE4	COMPLETED	Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
NCT00522470	PHASE4	COMPLETED	Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels